Literature DB >> 2784463

Lymphocyte activation provokes modification of a lymphocyte-specific protein tyrosine kinase (p56lck).

J D Marth1, D B Lewis, M P Cooke, E D Mellins, M E Gearn, L E Samelson, C B Wilson, A D Miller, R M Perlmutter.   

Abstract

The protein tyrosine kinase p56lck is implicated in the control of lymphocyte growth by virtue of its overexpression in some lymphoid malignancies and its transforming activity in heterologous systems. Previous studies have demonstrated that levels of lck mRNA and of p56lck decline rapidly after T cell activation. The disappearance of p56lck results primarily from post-translational conversion of p56lck to more slowly migrating forms with apparent sizes of approximately 60 kDa. This modification can be provoked by treatment of lymphocytes with PMA, and has been associated with increased serine phosphorylation of the p56lck molecule. Here we demonstrate that conversion of p56lck to p60lck is a feature of the physiologic activation of T lymphocytes by antigen-presenting cells. In addition, we show that the PMA-induced modification of p56lck proceeds via a mechanism distinct from conventional protein kinase C activation. The rapid conversion of p56lck to p60lck after antigenic stimulation is consistent with the view that this membrane-associated protein tyrosine kinase regulates some aspects of the lymphocyte activation sequence.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784463

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Disruption of the CD4-p56lck complex is required for rapid internalization of CD4.

Authors:  B P Sleckman; J Shin; V E Igras; T L Collins; J L Strominger; S J Burakoff
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

2.  Lack of SHPTP1 results in src-family kinase hyperactivation and thymocyte hyperresponsiveness.

Authors:  U Lorenz; K S Ravichandran; S J Burakoff; B G Neel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

3.  Activation of resting human T cells requires prolonged stimulation of protein kinase C.

Authors:  N Berry; K Ase; A Kishimoto; Y Nishizuka
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

4.  DEF-1, a novel Src SH3 binding protein that promotes adipogenesis in fibroblastic cell lines.

Authors:  F J King; E Hu; D F Harris; P Sarraf; B M Spiegelman; T M Roberts
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

Review 5.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

6.  Herpes simplex virus requires VP11/12 to induce phosphorylation of the activation loop tyrosine (Y394) of the Src family kinase Lck in T lymphocytes.

Authors:  Melany J Wagner; James R Smiley
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

7.  Anergic T-lymphocyte clones have altered inositol phosphate, calcium, and tyrosine kinase signaling pathways.

Authors:  T F Gajewski; D Qian; P Fields; F W Fitch
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

8.  Human immunodeficiency virus type 1 Nef protein inhibits activation pathways in peripheral blood mononuclear cells and T-cell lines.

Authors:  A Greenway; A Azad; D McPhee
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

9.  A colony-stimulating factor 1 (CSF-1) receptor/platelet-derived growth factor-beta receptor gene fusion confers CSF-1 independence and tumorigenicity on a c-myc-immortalized monocyte cell line.

Authors:  M R Eccles; F J King; M D Cole
Journal:  Mol Cell Biol       Date:  1992-01       Impact factor: 4.272

10.  Human immunodeficiency virus type 1 Nef and p56lck protein-tyrosine kinase interact with a common element in CD4 cytoplasmic tail.

Authors:  S Salghetti; R Mariani; J Skowronski
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.